Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/236583
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
DC FieldValueLanguage
dc.contributor.authorChen, Minjiees_ES
dc.contributor.authorSun, Xicuies_ES
dc.contributor.authorWei, Weies_ES
dc.contributor.authorCucarella, Carmees_ES
dc.contributor.authorMartín-Sanz, Palomaes_ES
dc.contributor.authorCasado, Martaes_ES
dc.contributor.authorPi, Liyaes_ES
dc.contributor.authorRen, Bines_ES
dc.contributor.authorCao, Qies_ES
dc.date.accessioned2021-03-31T13:33:10Z-
dc.date.available2021-03-31T13:33:10Z-
dc.date.issued2021-03-02-
dc.identifier.citationAlcohol 92:41-52 (2021)es_ES
dc.identifier.issn0741-8329-
dc.identifier.urihttp://hdl.handle.net/10261/236583-
dc.description12 páginas, 5 figuras, 2 tablases_ES
dc.description.abstractPurpose: A diet high in fat and ethanol often results in chronic metabolic disorder, hepatic steatosis, and liver inflammation. Constitutive hepatic cyclooxygenase-2 (COX-2) expression could protect from high fat-induced metabolism disturbance in a murine model. In this study, we explored the influence of hCOX-2 transgenic [TG] to high fat with ethanol-induced metabolic disorder and liver injury using a mouse animal model. Methods: 12-week-old male hepatic hCOX-2 transgenic (TG) or wild type mice (WT) were fed either a high fat and ethanol liquid diet (HF+Eth) or a regular control diet (RCD) for 5 weeks (four groups: RCD/WT, RCD/TG; HF+Eth/TG, HF+Eth/WT). We assessed metabolic biomarkers, cytokine profiles, histomorphology, and gene expression to study the impact of persistent hepatic COX-2 expression on diet-induced liver injury. Results: In the HF+Eth diet, constitutively hepatic human COX-2 expression protects mice from body weight gain and white adipose tissue accumulation, accompanied by improved IPGTT response, serum triglyceride/cholesterol levels, and lower levels of serum and liver inflammatory cytokines. Histologically, hCOX-2 mice showed decreased hepatic lipid droplets accumulation, decreased hepatocyte ballooning, and improved steatosis scores. Hepatic hCOX-2 overexpression enhanced AKT insulin signaling and increased fatty acid synthesis in both RCD and HF+Eth diet groups. The anti-lipogenic effect of hCOX-2 TG in the HF+Eth diet animals was mediated by increasing lipid disposal through enhanced β-oxidation via elevations in the expression of PPARα and PPARγ, and increased hepatic autophagy as assessed by the ratio of autophagy markers LC3 II/I in hepatic tissue. Various protein acetylation pathway components, including HAT, HDAC1, SIRT1, and SNAIL1, were modulated in hCOX-2 TG mice in either RCD or HF+Eth diet. Conclusions: Hepatic human COX-2 expression protected mice from the metabolic disorder and liver injury induced by a high fat and ethanol diet by enhancing hepatic lipid expenditure. Epigenetic reprogramming of diverse metabolic genes might be involved in the anti-lipogenic effect of COX-2.es_ES
dc.description.sponsorshipThis work was supported by NIH grant (K08AA024895 to Q.C), Department Chair Research Fund of UMB (Q.C), GE Healthcare/ RSNA Research Resident Grant (#RR1250 to Q.C), Innovation Seed Grant of UMB (Q.C), Ministry of Economy and Competitiveness (MINECO, Spain. SAF2016-75004-R to P.M.S. and M.C) and NIH grant (1R01AA028035-01 to L.P).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relationMINECO/ICTI2013-2016/SAF2016-75004-Res_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsopenAccesses_ES
dc.subjectCOX-2es_ES
dc.subjectFatty liver diseasees_ES
dc.subjectMetabolismes_ES
dc.subjectProtein acetylationes_ES
dc.titleHepatic COX-2 expression protects mice from an alcohol-high fat dietinduced metabolic disorder by involving protein acetylation related energy metabolismes_ES
dc.typeartículoes_ES
dc.identifier.doi10.1016/j.alcohol.2020.08.007-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttps://dx.doi.org/10.1016/j.alcohol.2020.08.007es_ES
dc.identifier.e-issn1873-6823-
dc.rights.licensehttp://creativecommons.org/licenses/by/4.0/es_ES
dc.contributor.funderNational Institutes of Health (US)es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/100000002es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.pmid33662521-
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.languageiso639-1en-
item.openairetypeartículo-
Appears in Collections:(IIBM) Artículos
(IBV) Artículos
Files in This Item:
File Description SizeFormat
2021 Alcohol 92-41.pdf1,98 MBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

51
checked on May 16, 2022

Download(s)

53
checked on May 16, 2022

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.